Update on the mechanisms of action of anti‑TNF-α antibodies and their clinical implications in inflammatory bowel disease.

@article{Eder2016UpdateOT,
  title={Update on the mechanisms of action of anti‑TNF-α antibodies and their clinical implications in inflammatory bowel disease.},
  author={P. Eder and K. Linke and J. Witowski},
  journal={Polskie Archiwum Medycyny Wewnetrznej},
  year={2016},
  volume={126 10},
  pages={
          772-780
        }
}
The mechanisms of action of antitumor necrosis factor α (anti-TNF-α) antibodies in the therapy of inflammatory bowel disease (IBD) are not completely understood. Binding of antibodies to transmembrane TNF-α seems to be crucial for the induction of several cellular responses, including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and reverse signaling. However, these processes alone do not fully explain the diversity of responses to anti-TNF-α therapy seen in… Expand
8 Citations
No effect of anti-TNF-α treatment on serum IL-17 in patients with rheumatoid arthritis
  • 2
  • PDF
PEG-b-(PELG-g-PLL) nanoparticles as TNF-α nanocarriers: potential cerebral ischemia/reperfusion injury therapeutic applications
  • 22
  • PDF

References

SHOWING 1-10 OF 74 REFERENCES
Approach to Optimize Anti-TNF-α Therapy in Patients With IBD
  • 15
Biologic targeting in the treatment of inflammatory bowel diseases
  • 121
  • PDF
Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease
  • 37
...
1
2
3
4
5
...